Cargando…

PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin

According to current US Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidance documents, physiologically based pharmacokinetic (PBPK) modeling is a powerful tool to explore and quantitatively predict drug‐drug interactions (DDIs) and may offer an alternative to dedicated cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanke, Nina, Frechen, Sebastian, Moj, Daniel, Britz, Hannah, Eissing, Thomas, Wendl, Thomas, Lehr, Thorsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202474/ https://www.ncbi.nlm.nih.gov/pubmed/30091221 http://dx.doi.org/10.1002/psp4.12343

Ejemplares similares

Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug–Drug–Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole
por: Türk, Denise, et al.
Publicado: (2019)

Physiologically‐Based Pharmacokinetic Models for CYP1A2 Drug–Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam
por: Britz, Hannah, et al.
Publicado: (2019)

Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
por: Kuepfer, L, et al.
Publicado: (2016)

Alfentanil - midazolam vs alfentanil - propofol para anestesia de corta duración
por: Sánchez Pacheco, Carlos
Publicado: (1994)

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
por: Wendl, Thomas, et al.
Publicado: (2021)

Pharmacodynamic modeling of moderate sedation and rationale for dosing using midazolam, propofol and alfentanil
por: Liou, Jing-Yang, et al.
Publicado: (2023)

Clinical evaluation of the potential drug–drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam
por: Ren, Song, et al.
Publicado: (2021)

Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?
por: Frechen, Sebastian, et al.
Publicado: (2022)

Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models
por: Vossen, Michaela, et al.
Publicado: (2007)

Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
por: Becker, Corina, et al.
Publicado: (2013)

Applied Concepts in PBPK Modeling: How to Extend an Open Systems Pharmacology Model to the Special Population of Pregnant Women
por: Dallmann, André, et al.
Publicado: (2018)

Comprehensive Parent–Metabolite PBPK/PD Modeling Insights into Nicotine Replacement Therapy Strategies
por: Kovar, Lukas, et al.
Publicado: (2020)

Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2021)

Correction to: Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2022)

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole
por: Martin, Paul, et al.
Publicado: (2012)

Mycobacterium shinjukuense infection successfully treated with clarithromycin, rifampicin, and ethambutol
por: Nakamura, Kayo, et al.
Publicado: (2023)

The safety and efficacy of alfentanil combined with midazolam in fiberoptic bronchoscopy sedation: A randomized, double-blind, controlled trial
por: Wang, Longfei, et al.
Publicado: (2022)

Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates
por: Kovar, Lukas, et al.
Publicado: (2020)

Alfentanil etomidato vs alfentanil propofol en cirugía obstétrica de corta duración
por: Palacios Zárate, Aurora Alejandra
Publicado: (1998)

Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI
por: Jones, Nicholas S., et al.
Publicado: (2019)

Remifentanil or Alfentanil for Endotracheal Intubation
por: Bilotta, Federico, et al.
Publicado: (2012)

Use of Alfentanil in Palliative Care
por: Ferraz Gonçalves, José António, et al.
Publicado: (2020)

A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interactions
por: Frechen, Sebastian, et al.
Publicado: (2021)

Comparison of Sedation with Dexmedetomidine Alfentanil Versus Ketamine-Alfentanil in Patients Undergoing Closed Reduction of Nasal Fractures
por: Akhondzadeh, Reza, et al.
Publicado: (2020)

Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients
por: Kovar, Lukas, et al.
Publicado: (2020)

A Quantitative Systems Pharmacology Kidney Model of Diabetes Associated Renal Hyperfiltration and the Effects of SGLT Inhibitors
por: Balazki, Pavel, et al.
Publicado: (2018)

A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin
por: Balazki, Pavel, et al.
Publicado: (2020)

Anticoagulation in COVID-19: DDI Perspective
por: Khiali, Sajad, et al.
Publicado: (2020)

Cluster Gauss‐Newton method analyses of PBPK model parameter combinations of coproporphyrin‐I based on OATP1B‐mediated rifampicin interaction studies
por: Yoshikado, Takashi, et al.
Publicado: (2022)

PBPK modeling and simulation in drug research and development
por: Zhuang, Xiaomei, et al.
Publicado: (2016)

Evaluation of the Pharmacokinetic Drug Interaction of Capmatinib With Itraconazole and Rifampicin and Potential Impact on Renal Transporters in Healthy Subjects
por: Cui, Xiaoming, et al.
Publicado: (2022)

Mechanistically Coupled PK (MCPK) Model to Describe Enzyme Induction and Occupancy Dependent DDI of Dabrafenib Metabolism
por: Albrecht, Marco, et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)

Model reduction in mathematical pharmacology: Integration, reduction and linking of PBPK and systems biology models
por: Snowden, Thomas J., et al.
Publicado: (2018)

Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug‐Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects
por: Asaumi, Ryuta, et al.
Publicado: (2018)

Inappropriate use of digoxin in patients presenting with digoxin toxicity
por: Tatlisu, Mustafa Adem, et al.
Publicado: (2015)

Moderate sedation by total intravenous remimazolam-alfentanil vs. propofol-alfentanil for third molar extraction: A prospective randomized controlled trial
por: Zhao, Nan, et al.
Publicado: (2022)

Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial
por: Phillips, Richard O, et al.
Publicado: (2020)

Predictive Performance of Physiology‐Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small‐Molecule Compounds in Children
por: Ince, Ibrahim, et al.
Publicado: (2021)

Effects of itraconazole and rifampicin on the single‐dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hg5tomett50at29ft0epq0ni8h